Sophiris Bio, Inc. (SPHS) Stock: A Biotech Stock That’s Seeing Strong Declines


Sophiris Bio, Inc. (SPHS) is trending down in the market in today’s trading session. The company, focused on the biotech sector, is presently trading at $0.95 after heading down -13.96% so far in today’s session. As it relates to biotech companies, there are several aspects that have the potential to generate movement in the market. One of the most common is news. Here are the most recent trending headlines centered around SPHS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-20-19 09:50AM SPHS: Details of Phase 3 Prostate Cancer Trial Based on Positive EMA Feedback
Jun-19-19 08:30AM Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
Jun-14-19 07:21AM Some Sophiris Bio (FRA:BFF1) Shareholders Have Taken A Painful 79% Share Price Drop
May-14-19 09:30AM SPHS: EMA Guidance on Phase 3 Clinical Trial for Topsalysin Expected in 2Q19
May-09-19 04:05PM Sophiris Bio Reports First Quarter 2019 Financial Results

However, any time investors are making a decision with regard to investing, prospective investors should look into far more than just news, especially in the highly speculative biotechnology sector. Here’s what’s happening in regard to Sophiris Bio, Inc..

What We’ve Seen From SPHS

While a single session decline, like the move that we’re seeing from Sophiris Bio, Inc. might cause fear in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It is generally important to dig into trends experienced by the stock for a period longer than a single trading day. In the case of SPHS, here are the returns that investors have seen:

  • Past 5 Trading Sessions – Over the last 7 days, SPHS has generated a change in value in the amount of 1.60%.
  • Monthly – The monthly ROI from Sophiris Bio, Inc. works out to 26.52%.
  • Past Three Months – In the past 3 months, the stock has produced a return that works out to -10.33%
  • Bi-Annually – Over the last 6 months, we’ve seen a change that works out to -17.67% from the stock.
  • YTD – Since the close of last year SPHS has produced a return of 15.06%.
  • Full Year – Lastly, over the last year, we’ve seen performance of -67.95% from SPHS. Over this period, the stock has traded at a high of -72.64% and a low price of 34.51%.

Rations That You Should Think About

Digging into a few ratios having to do with a stock generally gives traders a view of how dangerous and/or rewarding a pick might be. Below are a few of the important ratios to look at when looking at SPHS.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it shows that more investors have a belief that the stock is going to fall. Across the sector, biotechnology stocks tend to come with a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, in relation to Sophiris Bio, Inc., the stock’s short ratio comes to 10.12.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure the company’s abilities to cover its debts when they mature based on current assets or quick assets. Because many biotech many companies rely on the continuation of support from investors, these ratios can seem damning. However, quite a few gems in the biotechnology sector do have positive quick and current ratios. As it relates to SPHS, the quick and current ratios add up to 2.00 and 2.00 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this case, the book to share value ratio comes in at -0.01.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotechnology space, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.30.

Analyst Opinions With Regard To Sophiris Bio, Inc.

Although it’s rarely a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their opinions to validate your own thoughts before making an investment decision in the biotechnology sector. Here are the most recent moves that we have seen from analysts as it relates to SPHS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-14-18 Reiterated Maxim Group Buy $6 → $5
Mar-13-17 Initiated Rodman & Renshaw Buy $6
Sep-15-16 Initiated ROTH Capital Buy $8
Aug-30-16 Initiated Piper Jaffray Overweight $7
Aug-10-16 Reiterated Maxim Group Buy $4 → $6

What Institutions And Insiders Think Of Sophiris Bio, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SPHS, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own 7.70% of Sophiris Bio, Inc.. Nonetheless, it is important to note that the ownership held by institutions has seen a move of -3.72% in the last 3 months.
  • Insider Moves – As far as insiders go, insiders of the company currently hold 0.85% of the company. Their ownership of the company has seen a change of 0.00% in the last quarter.

What’s The Float Looking Like?

Traders seem to be interested in the amounts of shares both available and outstanding. As far as Sophiris Bio, Inc., there are currently 30.22M with a float of 29.96M. These data mean that of the total of 30.22M shares of SPHS currently in existence today, 29.96M are able to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SPHS, the short percent of the float is 6.24%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.47. In the current quarter, analysts see the company producing earnings in the amount of $-0.10. Over the last 5 years, SPHS has generated revenue in the amount of $0 with earnings coming in at 30.50%. On a quarter over quarter basis, earnings have seen movement of 29.40% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here